Xeno Diagnostics Adds Dr. Daniel Wierda as Director of Research and Development

Share Article

Addition of Top Talent Strengthens Fast-growing Indianapolis Biotech CRO

Xeno Diagnostics, LLC, announced today that Dr. Daniel Wierda has joined Xeno as their new Director of Research and Development. Dan brings with him a great depth of experience in the area of immunotoxicology and cell-based assays. Prior to joining Xeno, Dan worked for 22 years at Eli Lilly and Company as a research scientist and toxicologist, where he oversaw a laboratory dedicated to investigative immunotoxicology. His laboratory performed a wide breadth of in vitro and ex vitro immune cell assays designed to characterize potentially immunomodulatory chemicals, and to evaluate the immunogenicity of biotherapeutics.

While working as a consultant for Xeno Diagnostics, it became apparent that his unique skill set and knowledge in the field of cell-based immunoassays is a perfect match for the direction that Xeno Diagnostics is now taking. Dan Follas, President & CEO of Xeno Diagnostics comments, “We are very pleased to have Dr. Wierda join Xeno Diagnostics. Dan’s experience working within the regulatory landscape of the pharmaceutical industry not only facilitates Xeno’s ability to add new testing services, but also assures our clients that their product evaluation testing is performed under proper regulatory compliance.”

Dr. Wierda looks forward to the opportunities presented in this new role, “I am very excited about joining Xeno Diagnostics. I was initially surprised to find a lab in the Indianapolis area offering immune cell, tissue culture services, and was equally delighted to find that this included flow cytometry capabilities. The Xeno staff is exceptionally versatile and dedicated, and through the leadership of its President and Lead Scientist, Dan Follas, has established a reputation as a dependable service provider of cell-based assays. I am looking forward to helping expand their repertoire of services, and also in working with their clients and scientists on developing fit-for-purpose cell-based assays that meet individual regulatory or research needs.”

About Xeno Diagnostics:

Xeno Diagnostics was founded in 2007 by Dan Follas, with the mission of making more products and services available for researchers studying porcine models of disease and inflammation. Early focus was solely on porcine models; the development of antibodies, test procedures, and functional cell-based assays. It was quickly noticed that clients requested cell-based assays, but in other animal models. Xeno quickly adapted, and now offers assays for many species, including non-human primates (baboon, cynomolgus macaque, and rhesus macaque) bovine, and human. At present, Xeno now focuses on providing high-quality, GLP compliant cell-based assays. These assays are of particular interest to organizations looking to move their products or technologies through the regulatory landscape. Xeno has found great success in being able to provide solutions for the unique challenges faced by organizations with implantable tissues and devices. To learn more about Xeno Diagnostics and their contract research services, visit http://www.xenodiagnostics.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jon Follas
Xeno Diagnostics, LLC

Visit website